Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Infection and Drug Resistance
- Vol. 13, 4475-4486
- https://doi.org/10.2147/IDR.S278020
Abstract
Purpose: The study aimed to evaluate meropenem, fosfomycin, berberine hydrochloride, and doxycycline minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae collected from eight provinces in China in 2018. Methods: The MICs of 540 Neisseria gonorrhoeae isolates (451 isolates selected randomly and 89 isolates selected with preference) were determined to meropenem, fosfomycin, berberine hydrochloride, and doxycycline using the agar dilution method, and the MICs of ceftriaxone and azithromycin were detected for comparison. Results: Among 451 randomly selected isolates, the MIC 90 was 0.06 mg/L for meropenem, 64 mg/L for fosfomycin, 64 mg/L for berberine hydrochloride, and 16 mg/L for doxycycline. All isolates showed the MIC <= 0.125 mg/L to meropenem, 13 isolates (2.9%) showed MIC > 64 mg/L to fosfomycin, 8 isolates (1.8%) demonstrated MIC > 64 mg/L to berberine hydrochloride, and 271 isolates (60.1%) demonstrated MIC > 1 mg/L to doxycycline. Comparing all 540 tested isolates, a correlation of r = 0.50 (P < 0.001) between meropenem and ceftriaxone MIC was observed. In 24 ceftriaxone-decreased susceptibility isolates, all isolates showed an MIC < 0.125 mg/L for meropenem, 1 isolate (4.2%) showed an MIC > 64 mg/L for fosfomycin, 1 isolate (4.2%) showed an MIC > 64 mg/L for berberine hydrochloride, and 13 isolates (54.2%) showed an MIC > 1 mg/L for doxycycline. In 87 azithromycin resistant isolates, all isolates showed an MIC <= 0.125 mg/L for meropenem, 2 isolates (2.3%) showed an MIC > 64 mg/L for fosfomycin, 4 isolates (4.6%) showed an MIC > 64 mg/L for berberine hydrochloride, and 64 isolates (73.6%) showed an MIC > 1 mg/L for doxycycline. Conclusion: The in vitro results suggest that meropenem might be a promising treatment option for resistant gonococcal infections, while the effects of fosfomycin and berberine hydrochloride should be further evaluated as potential therapeutic agents. The effectiveness of these drugs in animal experiments and clinical use may need further study.This publication has 35 references indexed in Scilit:
- Tissue Distribution of Berberine and Its Metabolites after Oral Administration in RatsPLOS ONE, 2013
- High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment FailureAntimicrobial Agents and Chemotherapy, 2012
- Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to CeftriaxoneAntimicrobial Agents and Chemotherapy, 2011
- Extracts of Canadian First Nations Medicinal Plants, Used as Natural Products, Inhibit Neisseria gonorrhoeae Isolates With Different Antibiotic Resistance ProfilesSexually Transmitted Diseases, 2011
- Genetic Evidence for Inhibition of Bacterial Division Protein FtsZ by BerberinePLOS ONE, 2010
- Berberine: a potential phytochemical with multispectrum therapeutic activitiesExpert Opinion on Investigational Drugs, 2010
- Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberinePhytotherapy Research, 2008
- Berberine Targets Assembly of Escherichia coli Cell Division Protein FtsZBiochemistry, 2008
- Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coliAntimicrobial Agents and Chemotherapy, 1988
- Bacteriological Evaluation of Fosfomycin in Clinical StudiesChemotherapy, 1977